Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
7.73% | 7.69% | 8.38% | 8.42% | |
| 4.11% | 4.07% | 4.42% | 4.26% | ||
ROIC |
5.44% | 5.41% | 5.43% | 5.28% | |
Return on Tangible Assets |
4.50% | 4.51% | 4.74% | 4.69% | |
Average Days of Receivables |
4.49 | 4.50 | 4.11 | 4.53 | |
Free Cash Flow per Share |
7.95 | 5.79 | 2.74 | 2.94 | |
Free Cash Flow |
3,432.44 | 2,489.82 | 1,195.57 | 1,310.08 | |
Capital Expenditures |
1,027.24 | — | (1,416.41) | (1,666.37) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
12.32% | 12.90% | 13.39% | 15.20% | |
Accounts Receivable Turnover |
87.35 | 84.52 | 95.15 | 85.65 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
17.11% | 19.01% | 18.08% | 9.41% | |
Selling, General and Administrative Expense of Revenue |
20.29% | 24.11% | 25.50% | 23.83% | |
Share Based Compensation of Revenue |
7.01% | 12.19% | 16.86% | 16.86% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.13 | 3.23 | 3.16 | 3.67 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
35.35 | 0.00 | (39.29) | (46.64) | |
Revenue per Share |
5.44 | 5.53 | 5.59 | 5.70 | |
Operating CF per Share |
5.57 | 5.79 | 5.98 | 6.69 | |
Capex per Share |
2.38 | 0.00 | (3.24) | (3.74) | |
Capex to Sales |
(0.44) | 0.00 | 0.58 | 0.66 | |
Net Profit Margin |
32.68% | 32.42% | 33.86% | 32.02% |
Columns are period end dates